Rchr
J-GLOBAL ID：201301080014062534
Update date: Jun. 25, 2024
YAMAGUCHI OU
ヤマグチ オウ | YAMAGUCHI OU
Affiliation and department：
Job title：
Lecturer
Papers (23)：
-
Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Shun Shinomiya, Tomoe Akagami, Hisao Imai, Kunihiko Kobayashi, et al. Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers. Frontiers in oncology. 2021. 11. 610952
-
Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Shun Shinomiya, Tomoe Akagami, Hisao Imai, Kunihiko Kobayashi, et al. Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers. Frontiers in oncology. 2021. 11. 610952
-
Yamaguchi O, Kaira K, Shinomiya S, Mouri A, Hashimoto K, Shiono A, Miura Y, Akagami T, Imai H, Kobayashi K, et al. Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumab. Thoracic Cancer. 2021. 12. 3. 304-313
-
Ou Yamaguchi, Kyoichi Kaira, Kosuke Hashimoto & Hiroshi Kagamu. Detection of pseudoprogression with [ 18 F]-FDG-PET in a patient with pulmonary large cell neuroendocrine carcinoma who received anti-PD-1 treatment. European journal of nuclear medicine and molecular imaging. 2020. 481. 1268-1270
-
Ou Yamaguchi, Kyoichi Kaira, Kosuke Hashimoto & Hiroshi Kagamu. Detection of pseudoprogression with [ 18 F]-FDG-PET in a patient with pulmonary large cell neuroendocrine carcinoma who received anti-PD-1 treatment. European journal of nuclear medicine and molecular imaging. 2020. 481. 1268-1270
ｍore...
Education (1)：
- 2000 - 2006 Saitama Medical University
Return to Previous Page
